MedTrace Logo

Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer

NCT01266057 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2021-03-04

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of sirolimus or vorinostat that can be given in combination with hydroxychloroquine to patients with advanced cancer. The safety of these drug combinations will also be studied.

Conditions

Interventions

DRUG

Hydroxychloroquine

Starting dose of 200 mg by mouth every day for a 21 day cycle.

DRUG

Sirolimus

Starting dose of 2 mg by mouth every day for a 21 day cycle.

DRUG

Vorinostat

Starting dose of 200 mg by mouth per day for a 21 day cycle.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Filip Janku, MD, PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-28
Primary Completion
2021-02-11
Completion
2021-02-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01266057 on ClinicalTrials.gov